Efficacy of Pembrolizumab and Olaparib Combination Observed in a Subset of Patients with HRD Metastatic Pancreatic Cancer By Ogkologos - April 7, 2026 230 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POLAR study Source RELATED ARTICLESMORE FROM AUTHOR Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide Aiming to Support Cancer Research, ESMO Calls on the European Council to Allocate a Budget of at Least €220 Billion to Horizon Europe MOST POPULAR How Anxiety Impacts People With Cancer and How to Cope February 10, 2022 A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with... January 12, 2026 Pivotal Role of the Institutional Molecular Tumour Board in Evaluating the... September 10, 2021 Darolutamide Maintenance Improves Outcomes in Patients with mCRPC Who Were Previously... March 2, 2023 Load more HOT NEWS Time to take on 9 new Cancer Grand Challenges April is Occupational Therapy (OT) Month- What is OT and how... Finally Pregnant After Struggling With Infertility For Years, She Was Diagnosed... A Painful Breast Lump May Be Mistaken For Cancer When It’s...
